5-溴苯并咪唑-2-甲酸 | 40197-20-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-溴苯并咪唑-2-甲酸
• 中文别名: 6-溴-1H-苯并咪唑-2-羧酸；5-溴-1H-苯并咪唑-2-羧酸；5-溴-1-氢-苯并咪唑-2-甲酸
• 英文名称: 5-bromo-1H-benzimidazol-2-carboxylic acid
• 英文别名: 5-bromo-1H-benzo[d]imidazole-2-carboxylic acid；5-bromo-1H-benzimidazole-2-carboxylic acid；5-Bromo-1H-benzoimidazole-2-carboxylic acid；6-bromo-1H-benzimidazole-2-carboxylic acid
• CAS: 40197-20-4
• 化学式: C₈H₅BrN₂O₂
• 分子量: 241.044
• InChiKey: ULTDLMITPWHISY-UHFFFAOYSA-N

物化性质

• 熔点：
  206℃
• 沸点：
  495℃
• 密度：
  1.946
• 闪点：
  253℃

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-1h-benzoimidazole-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-1h-benzoimidazole-2-carboxylic acid
CAS number: 40197-20-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5BrN2O2
Molecular weight: 241.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴苯并咪唑-2-甲酸 在 盐酸 、 四(三苯基膦)钯 、 10 wt% Pd(OH)2 on carbon 、 氢气 、 sodium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 [5-(piperidin-4-yl)-1H-benzimidazol-2-yl]{4-[4-(trifluoromethyl)benzyl]piperazin-1-yl}methanone
  参考文献：
  名称：

  开发一种有效的，口服活性的腺苷单磷酸激活蛋白激酶（AMPK）激活剂ASP4132，作为治疗人类癌症的临床候选药物。

  摘要：

  单磷酸腺苷（AMP）激活的蛋白激酶（AMPK）在维持细胞代谢中起关键作用。AMP或二磷酸腺苷（ADP）的水平在代谢应激期间（例如在营养缺乏，缺氧和肌肉收缩过程中）升高，并与AMPK结合以诱导活性。近来，AMPK的激活已被认为是人类肿瘤学领域中有吸引力的治疗策略。铅化合物2的结构优化，一种新型AMPK活化剂，具有强大的AMPK活化活性和对人类癌细胞的有吸引力的选择性生长抑制作用，改善了水溶性，代谢稳定性和动物药代动力学（PK），最终鉴定为（5- { 1-[（（6-甲氧基吡啶-3-基）甲基]哌啶-4-基} -1H-苯并咪唑-2-基）（4-{[4-（三氟甲基）苯基]甲基}哌嗪-1-基）甲酮二甲苯磺酸盐，ASP4132（28）。ASP4132的研究已经发展到用于治疗癌症的临床试验。

  DOI：

  10.1016/j.bmc.2020.115307
• 作为产物：
  描述：

  4-溴邻苯二胺 在 盐酸 、 potassium permanganate 作用下， 以 水 、 丙酮 为溶剂， 反应 8.0h， 生成 5-溴苯并咪唑-2-甲酸
  参考文献：
  名称：

  选定的苯并咪唑衍生物作为潜在抗菌剂的合成与评价。

  摘要：

  合成了53个苯并咪唑衍生物的文库，它们在1、2和5位具有取代基，并针对一系列与医学相关的细菌和真菌参考菌株进行了筛选。SAR分析最有前景的结果表明，化合物的抗菌活性取决于与双环杂环相连的取代基。特别是，某些化合物对两种耐甲氧西林的金黄色葡萄球菌（MRSA）菌株表现出抗菌活性，其最低抑制浓度（MIC）与广泛使用的环丙沙星药物相当。这些化合物具有一些共同特征。三个具有5-卤素取代基；两个是（S）-2-乙胺苯并咪唑的衍生物；其他是一种2-（氯甲基）-1H-苯并[d]咪唑和（1H-苯并[d]咪唑-2-基）甲硫醇的衍生物。抗真菌筛选的结果也非常有趣：23种化合物对选定的真菌菌株显示出有效的杀真菌活性。它们的MIC值显示出比两性霉素B相同或更高的效力。5-卤代苯并咪唑衍生物被认为是有前途的广谱抗微生物候选物，值得进一步研究以用于潜在的治疗应用。

  DOI：

  10.3390/molecules200815206

文献信息

• [EN] BACTERIAL EFFLUX PUMP INHIBITORS<br/>[FR] INHIBITEURS DE POMPE D'EFFLUX BACTÉRIEN
  申请人：LAVOIE EDMOND J

  公开号：WO2018165612A1

  公开（公告）日：2018-09-13

  Disclosed herein are compounds of formula I and salts thereof. Also disclosed are compositions comprising compounds of formula I and methods using compounds of formula I.

  本文披露了公式I的化合物及其盐。还披露了包含公式I化合物的组合物和使用公式I化合物的方法。
• [EN] SMALL MOLECULE DEGRADERS OF STAT3<br/>[FR] AGENTS DE DÉGRADATION, À PETITES MOLÉCULES, DE STAT3
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2020198435A1

  公开（公告）日：2020-10-01

  The present disclosure provides compounds represented by Formula I or Formula VIII: wherein R1a, R1b, M, A, E, QA, and QB are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3 or dedraders of STAT3 and STAT1. Compounds of Formula VIII are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.

  本公开提供由公式I或公式VIII表示的化合物：其中R1a、R1b、M、A、E、QA和QB如规范中定义，并其盐和溶剂合物。公式I的化合物是STAT3的降解物或STAT3和STAT1的去除物。公式VIII的化合物是STAT3的抑制剂。STAT3的降解物和抑制剂对于癌症和其他疾病的治疗是有用的。
• [EN] STAT3 PROTEIN DEGRADERS<br/>[FR] AGENTS DE DÉGRADATION DE PROTÉINES STAT3
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2020205467A1

  公开（公告）日：2020-10-08

  The present disclosure provides compounds represented by Formulae I and IV: wherein R1a, R1b, R2a, R2b, A, E, QD, and QE are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3. Compounds of Formula IV are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.

  本公开提供由式I和式IV表示的化合物：其中R1a、R1b、R2a、R2b、A、E、QD和QE如规范中定义，并其盐和溶剂合物。式I的化合物是STAT3的降解剂。式IV的化合物是STAT3的抑制剂。STAT3的降解剂和抑制剂对于癌症和其他疾病的治疗是有用的。
• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015086642A1

  公开（公告）日：2015-06-18

  This application discloses compounds according to generic Formula (I) wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.

  本申请揭示了根据通用式（I）定义的化合物，其中所有变量如本文所述，这些化合物抑制Btk。本文披露的化合物对调节Btk的活性并治疗与Btk过度活性相关的疾病有用。这些化合物对于治疗由异常B细胞活化引起的肿瘤、自身免疫和炎症性疾病有用。还披露了含有通用式（I）化合物和至少一种载体、稀释剂或赋形剂的组合物。
• [EN] NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS<br/>[FR] NOUVEAUX DÉRIVÉS D'INDOLE SUBSTITUÉS UTILISÉS EN TANT QUE MODULATEURS DE LA GAMMA-SÉCRÉTASE
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2013010904A1

  公开（公告）日：2013-01-24

  The present invention is concerned with novel substituted indole derivatives of Formula (I) wherein R1, R2, R3, A1, A2, A3, Y and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及具有以下式（I）中R1、R2、R3、A1、A2、A3、Y和X所定义含义的新型取代吲哚衍生物。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新型化合物的方法，包含该化合物作为活性成分的药物组合物，以及将该化合物用作药物的用途。